Analysts See $-0.01 EPS for Surmodics, Inc. (SRDX)

April 25, 2018 - By Adrian Erickson

Surmodics, Inc. (NASDAQ:SRDX) LogoInvestors sentiment decreased to 0.69 in Q4 2017. Its down 0.25, from 0.94 in 2017Q3. It dived, as 11 investors sold Surmodics, Inc. shares while 44 reduced holdings. 12 funds opened positions while 26 raised stakes. 11.07 million shares or 0.98% less from 11.18 million shares in 2017Q3 were reported.
Rice Hall James Assocs Lc reported 0.11% in Surmodics, Inc. (NASDAQ:SRDX). State Common Retirement Fund holds 0% or 15,300 shares in its portfolio. Foundry Prtn Lc holds 0.1% or 85,250 shares in its portfolio. Moreover, Fincl Bank Of Ny Mellon Corp has 0% invested in Surmodics, Inc. (NASDAQ:SRDX) for 155,922 shares. Wells Fargo Co Mn has 28,209 shares for 0% of their portfolio. Great West Life Assurance Can stated it has 0% of its portfolio in Surmodics, Inc. (NASDAQ:SRDX). Bank & Trust Of America Corporation De holds 17,305 shares. Dimensional Fund Advsrs Limited Partnership owns 636,801 shares. Comerica National Bank & Trust has 13,451 shares. Swiss Comml Bank has invested 0% in Surmodics, Inc. (NASDAQ:SRDX). Legal & General Group Public Limited Co has invested 0% in Surmodics, Inc. (NASDAQ:SRDX). Invesco Ltd holds 44,719 shares or 0% of its portfolio. Teachers Retirement System Of The State Of Kentucky owns 1,798 shares or 0% of their US portfolio. Menta Limited Co holds 0.29% or 52,923 shares. Disciplined Growth Invsts Inc Mn holds 0.1% of its portfolio in Surmodics, Inc. (NASDAQ:SRDX) for 178,854 shares.

Since December 11, 2017, it had 0 insider buys, and 2 insider sales for $63,711 activity.

Analysts expect Surmodics, Inc. (NASDAQ:SRDX) to report $-0.01 EPS on April, 26.They anticipate $0.06 EPS change or 120.00 % from last quarter’s $0.05 EPS. After having $0.10 EPS previously, Surmodics, Inc.’s analysts see -110.00 % EPS growth. The stock increased 0.67% or $0.25 during the last trading session, reaching $37.45. About 37,557 shares traded. Surmodics, Inc. (NASDAQ:SRDX) has risen 61.37% since April 26, 2017 and is uptrending. It has outperformed by 49.82% the S&P500.

Surmodics, Inc. (NASDAQ:SRDX) Ratings Coverage

Among 2 analysts covering Surmodics (NASDAQ:SRDX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Surmodics had 2 analyst reports since February 28, 2018 according to SRatingsIntel. The firm has “Outperform” rating given on Wednesday, February 28 by Barrington Research.

Surmodics, Inc., together with its subsidiaries, provides medical devices and in vitro diagnostic technologies to the healthcare industry in the United States and Ireland. The company has market cap of $494.21 million. It operates through two divisions, Medical Device and In Vitro Diagnostics. It has a 18725 P/E ratio. The Medical Device segment offers surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device for the coronary, peripheral, neuro-vascular, urology, and other markets.

Surmodics, Inc. (NASDAQ:SRDX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.